HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

oxaliplatin (Eloxatin)

Subscribe to New Research on oxaliplatin

RN given refers to (SP-4-2-(trans))-isomer

Also Known As:

Eloxatin; oxaliplatine; 1,2-diaminocyclohexane platinum oxalate; 1,2-diamminocyclohexane(trans-1)oxolatoplatinum(II); ACT 078; ACT-078; Eloxatine; Sanofi Synthelabo brand of oxaliplatin; Sanofi brand of oxaliplatin; cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II); oxalato-(1,2-cyclohexanediamine)platinum II; oxaliplatin, (SP-4-2-(1R-trans))-isomer; oxaliplatin, (SP-4-2-(1S-trans))-isomer; oxaliplatin, (SP-4-3-(cis))-isomer; platinum(II)-1,2-cyclohexanediamine oxalate

Networked: 4355 relevant articles (704 outcomes, 1546 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Goldberg, Richard M: 41 articles (04/2015 - 08/2002)
2.	de Gramont, Aimery: 39 articles (12/2015 - 04/2002)
3.	André, Thierry: 34 articles (12/2015 - 08/2002)
4.	Tabernero, Josep: 27 articles (12/2015 - 06/2004)
5.	Park, Young Suk: 27 articles (12/2015 - 07/2005)
6.	Saif, Muhammad Wasif: 26 articles (11/2015 - 01/2007)
7.	Van Cutsem, Eric: 24 articles (11/2015 - 04/2002)
8.	Lenz, Heinz-Josef: 24 articles (07/2013 - 06/2002)
9.	Louvet, Christophe: 23 articles (12/2015 - 08/2002)
10.	Grothey, Axel: 23 articles (10/2015 - 08/2003)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 08/23/2012 - "In contrast, oxaliplatin, containing the isomeric 1(R),2(R)-DACH carrier ligand, enjoys worldwide clinic application as a most important therapeutic agent in the treatment of colorectal cancer. " 10/01/2002 - "To date, oxaliplatin has proven to be a safe and effective therapy for colorectal cancer and side effects have been easy to manage with appropriate awareness from patients and care providers." 01/01/2004 - "Oxaliplatin combined with the bolus Nordic schedule of FU+FA (Nordic FLOX) is a well-tolerated, effective, and feasible bolus schedule as first-line treatment of metastatic colorectal cancer that yields comparable results compared with more complex schedules." 10/01/2003 - "Although no definitive data show one drug to be better than the other, several arguments favored the oxaliplatin/5-FU combination as a first-line treatment of metastatic colorectal cancer. " 01/01/2003 - "Oxaliplatin combined with the bolus Nordic schedule of 5-FU/ FA (Nordic FLOX) appears to be well tolerated, effective and feasible as first-line treatment of metastatic colorectal cancer yielding results comparable with those obtained by more complex schedules."
2.	Neoplasms (Cancer) 01/01/2010 - "In this experimental model, oxaliplatin was highly effective against intraperitoneal tumor spread but only with the intraperitoneal application route. " 10/01/2007 - "Anti-IGF-IR MoAB plus oxaliplatin led to a significantly greater inhibition of tumor growth. " 01/01/2014 - "Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin." 09/01/2012 - "Lipoxal also improved the specificity of oxaliplatin as shown by a higher ratio of tumor to right hemisphere uptake. " 02/01/2015 - "Oxaliplatin-based regimens are effective in metastasized advanced cancers. "
3.	Stomach Neoplasms (Stomach Cancer) 06/01/2010 - "In conclusion, patients with at least one (105)Val allele have better prognosis and response to oxaliplatin/5-FU-based regimen as first-line treatment for patients with advanced gastric cancer." 11/01/2012 - "The combination of oxaliplatin and S-1 is effective in patients with advanced gastric cancer. " 09/01/2007 - "Oxaliplatin was reportedly effective for metastatic gastric cancer, but it is still non-approved in Japan. " 08/02/2004 - "This oxaliplatin-containing regimen is effective in the treatment of advanced gastric cancer. " 05/01/2010 - "These findings indicate that SOX regimen with oxaliplatin at a dose of 100 mg/m(2) is feasible and shows promising efficacy against advanced gastric cancer."
4.	Colonic Neoplasms (Colon Cancer) 07/01/2009 - "CONCLUSION Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease." 06/01/2007 - "The addition of oxaliplatin to weekly FULV significantly improved DFS in patients with stage II and III colon cancer. " 11/01/2006 - "A review of the available evidence indicated that in patients with Stage III colon cancer, oxaliplatin in combination with an infusional de Gramont schedule of 5-FU/LV (FOLFOX4) was more effective in preventing and delaying disease recurrence than infusional 5-FU/LV alone (de Gramont regimen). " 11/01/2008 - "The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). " 11/01/2007 - "We therefore hypothesized that blocking oncogenic signaling with a Hsp90 inhibitor would impair metastatic behavior of colon cancer cells and also improve the efficacy of oxaliplatin in vivo. "
5.	Neoplasm Metastasis (Metastasis) 06/01/1999 - "Promising results have been found in studies of the drug as monotherapy, and oxaliplatin may also prove useful in the neoadjuvant setting in patients with unresectable liver metastases; however, data are limited at present." 01/01/2010 - "In vivo, 50% of all rats given 10 mg/kg oxaliplatin 24 h before thermal therapy were completely immunologically cured, while a further 11% regressed their primary tumour but ultimately succumbed to metastases, and 17% experienced a limited response with increased survival. " 04/01/2006 - "This study evaluates the effect of topical application of oxaliplatin on the development of port-site metastases in an experimental murine model. " 10/01/2002 - "In a recent study in 389 such patients, 151 of which had liver-only metastases, 51% treated with oxaliplatin became resectable with some patients achieving a complete histologic response. " 04/01/2015 - "Patients with cT4 and lateral pelvic lymph node metastasis, and without distant metastasis (cM0), were treated with weekly oxaliplatin, oral S-1 40 mg/m(2) twice daily for 5 days a week, and radiation. "

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	Leucovorin (Folinic Acid)
3.	irinotecan (Camptosar)
4.	capecitabine (Xeloda)
5.	bevacizumab
6.	gemcitabine
7.	cetuximab (Erbitux)
8.	Cisplatin (Platino)
9.	XELOX
10.	Platinum

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Adjuvant Chemotherapy
4.	Radiotherapy
5.	Neoadjuvant Therapy